Medizinische Universität Graz - Research portal
Selected Publication:
Aigner, RM; Fueger, GF; Zinke, W; Sill, H.
99Tcm-tetrofosmin scintigraphy in Hodgkin's disease.
Nucl Med Commun. 1997; 18(3):252-257
Doi: 10.1097/00006231-199703000-00009
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Aigner Reingard
- Co-authors Med Uni Graz
- Sill Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim of this study was to assess the suitability of 99Tcm-tetrofosmin (tetrofosmin) scintigraphy as a diagnostic modality in patients with Hodgkin's disease. Fourteen untreated patients with biopsy proven Hodgkin's disease (clinical stage Ia-IVb) were investigated. Post-treatment investigations were also done in 7 of the 14 patients. Focal pathological tetrofosmin uptake was seen in 42 site in the pre-treatment studies. Computed tomography identified 36 pathological regions. The tumour-to-background ratio ranged from 1.44 to 2.17 (mean 1.63). Follow-up studies demonstrated a response to treatment, in that there was a reduction in, or complete disappearance of, localized tetrofosmin uptake in regions previously pathological, and a decrease in tumour-to-background ratios. Tetrofosmin appears suitable for the localization of lymphomatous lesions, especially supradiaphragmatic ones, and for the follow-up of therapeutic response.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Female -
- Follow-Up Studies -
- Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin Disease - radionuclide imaging
- Humans -
- Male -
- Middle Aged -
- Neoplasm Staging -
- Organophosphorus Compounds - diagnostic use
- Organotechnetium Compounds - diagnostic use
- Reproducibility of Results -
- Time Factors -
- Tomography, Emission-Computed -